| Latest Breaking News from Modern Healthcare
| IOM: The doctor will see you TODAY should be standard | | Tuesday, June 30, 2015 6:00 PM | |
| | Provider-focused approaches to scheduling and failure to appropriately use nurse practitioners and physician assistants are among the reasons timely access to care remains a problem in the U.S., according to an Institute of Medicine report. |
| Healthcare workers wonder how expected overtime rule affects them | | Tuesday, June 30, 2015 6:00 PM | |
| | The home-care sector is keeping an eye out for an expected move by the White House to make up to 5 million more people eligible for overtime pay. Some say it could benefit fee-based employees while others believe it could cause employers to scale... |
| Which companies disclosed the most to Open Payments | | Tuesday, June 30, 2015 4:15 PM | |
| | Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data posted to the CMS' Open Payments website. |
| High court case could threaten union finances at public systems | | Tuesday, June 30, 2015 4:00 PM | |
| | The U.S. Supreme Court will hear a case asking it to limit the power of public unions to collect fees from nonmembers. The case could threaten the finances and membership efforts of unions that represent healthcare workers at publicly owned... |
| IOM reports 'unacceptable' disparities in cardiac arrest survival | | Tuesday, June 30, 2015 3:00 PM | |
| | A report from the Institute of Medicine suggests revamping the national strategy for cardiac arrest to standardize surveillance, coordination, data collection, public education and the sharing of best practices pertaining to the condition. |
| Celgene pays $1B to enter collaboration with Juno Therapeutics | | Tuesday, June 30, 2015 2:16 PM | |
| | Leading biotech firm Celgene Corp. will pay $1 billion to enter into a 10-year collaboration with Juno Therapeutics. The move broadens the company's cancer drug portfolio by gaining access to Juno's budding pipeline of oncology immunotherapies. |
|